mitoxantrone has been researched along with Chronic Progressive Multiple Sclerosis in 61 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The study's aim was to compare the efficacy and safety of intravenous cyclophosphamide (CTX) and mitoxantrone (MITO) as second-line therapy in a clinical sample of active relapsing-remitting (RR) or secondary-progressive (SP) multiple sclerosis subjects." | 9.13 | Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety. ( Amato, MP; Hakiki, B; Portaccio, E; Siracusa, G; Sorbi, S; Zipoli, V, 2008) |
| "Mitoxantrone (MX) has been shown to be moderately effective in reducing the clinical outcome measures of disease activity in multiple sclerosis (MS) patients." | 8.89 | Mitoxantrone for multiple sclerosis. ( Capra, R; Comi, G; Martinelli Boneschi, F; Rovaris, M; Vacchi, L, 2013) |
| "Mitoxantrone is a synthetic anthracenedione recently approved by the FDA for the treatment of worsening relapsing-remitting (RR), secondary progressive (SP), and progressive relapsing (PR) multiple sclerosis (MS)." | 8.82 | Review of mitoxantrone in the treatment of multiple sclerosis. ( Herndon, R; Jeffery, DR, 2004) |
| "The approval by the FDA of four immunomodulators (three IFNs and glatiramer acetate) and one immunosuppressant (mitoxantrone; Novantrone) for the treatment of multiple sclerosis is definitely the most important progress in this field since the first description of the disease > 150 years ago." | 8.82 | A comparison of the benefits of mitoxantrone and other recent therapeutic approaches in multiple sclerosis. ( Gonsette, RE, 2004) |
| "Six monthly courses of mitoxantrone were approved in France in 2003 for patients with highly active multiple sclerosis (MS)." | 8.12 | Ten-year follow-up after mitoxantrone induction for early highly active relapsing-remitting multiple sclerosis: An observational study of 100 consecutive patients. ( Edan, G; Kerbrat, A; Le Corre, G; Le Page, E; Le Port, D; Lefort, M; Leray, E; Michel, L; Rizzato, C, 2022) |
| "Mitoxantrone (MTX) has been used as an effective disease modifying treatment (DMT) in multiple sclerosis (MS)." | 7.96 | Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone. ( Foo, EC; Ford, HL; Lily, O; Russell, M, 2020) |
| "Two cases of therapy-related acute leukemia (TRAL) after the use of Mitoxantrone for the treatment of secondary progressive multiple sclerosis (MS) are reported." | 7.78 | Therapy-related acute leukemia in two patients with multiple sclerosis treated with Mitoxantrone. ( Colovic, N; Dencic Fekete, M; Djordjevic, V; Drulovic, J; Kraguljac Kurtovic, N; Suvajdzic, N; Tomin, D; Vidovic, A, 2012) |
| "The objective in this paper is to compare the cumulative incidence and incidence density of therapy-related acute myeloid leukaemia in two cohorts of patients with multiple sclerosis treated with mitoxantrone, and with previously reported data in the literature." | 7.75 | Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required. ( Abellán, I; Belenguer, A; Boscá, I; Casanova, B; Coret, F; Fernández, P; Magraner, MJ; Mallada, J; Montalbán, X; Pascual, AM; Sanz, MA; Sempere, AP; Téllez, N, 2009) |
| "Mitoxantrone is an approved drug for patients with worsening relapsing-remitting, secondary progressive and progressive relapsing multiple sclerosis (MS)." | 7.73 | Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone. ( Goffette, S; Morandini, E; Sindic, CJ; van Pesch, V; Vanoverschelde, JL, 2005) |
| "Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis (RENEW) was a 5-year, phase IV study in which the safety of Mitoxantrone was monitored in a patient cohort from the United States (US)." | 5.17 | Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study. ( Bock, D; Dangond, F; Jeffery, DR; Rivera, VM; Weinstock-Guttman, B, 2013) |
| "The study's aim was to compare the efficacy and safety of intravenous cyclophosphamide (CTX) and mitoxantrone (MITO) as second-line therapy in a clinical sample of active relapsing-remitting (RR) or secondary-progressive (SP) multiple sclerosis subjects." | 5.13 | Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety. ( Amato, MP; Hakiki, B; Portaccio, E; Siracusa, G; Sorbi, S; Zipoli, V, 2008) |
| "To evaluate the effects of mitoxantrone (Mx) in progressive multiple sclerosis (MS) on MRI." | 5.11 | Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial. ( Gonsette, R; Hartung, HP; Krapf, H; Morrissey, SP; Zenker, O; Zwingers, T, 2005) |
| "Mitoxantrone (MX) has been shown to be moderately effective in reducing the clinical outcome measures of disease activity in multiple sclerosis (MS) patients." | 4.89 | Mitoxantrone for multiple sclerosis. ( Capra, R; Comi, G; Martinelli Boneschi, F; Rovaris, M; Vacchi, L, 2013) |
| "The approval by the FDA of four immunomodulators (three IFNs and glatiramer acetate) and one immunosuppressant (mitoxantrone; Novantrone) for the treatment of multiple sclerosis is definitely the most important progress in this field since the first description of the disease > 150 years ago." | 4.82 | A comparison of the benefits of mitoxantrone and other recent therapeutic approaches in multiple sclerosis. ( Gonsette, RE, 2004) |
| " On the 29th of October 2003, mitoxantrone was approved by the french health agency Afssaps (Agence française de sécurité sanitaire des produits de santé) for its use in the aggressive forms of multiple sclerosis (MS)." | 4.82 | [Aggressive multiple sclerosis. Definition and specific therapeutic indication]. ( Edan, G, 2004) |
| "Mitoxantrone is a synthetic anthracenedione recently approved by the FDA for the treatment of worsening relapsing-remitting (RR), secondary progressive (SP), and progressive relapsing (PR) multiple sclerosis (MS)." | 4.82 | Review of mitoxantrone in the treatment of multiple sclerosis. ( Herndon, R; Jeffery, DR, 2004) |
| "Six monthly courses of mitoxantrone were approved in France in 2003 for patients with highly active multiple sclerosis (MS)." | 4.12 | Ten-year follow-up after mitoxantrone induction for early highly active relapsing-remitting multiple sclerosis: An observational study of 100 consecutive patients. ( Edan, G; Kerbrat, A; Le Corre, G; Le Page, E; Le Port, D; Lefort, M; Leray, E; Michel, L; Rizzato, C, 2022) |
| "Mitoxantrone (MTX) has been used as an effective disease modifying treatment (DMT) in multiple sclerosis (MS)." | 3.96 | Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone. ( Foo, EC; Ford, HL; Lily, O; Russell, M, 2020) |
| "Two cases of therapy-related acute leukemia (TRAL) after the use of Mitoxantrone for the treatment of secondary progressive multiple sclerosis (MS) are reported." | 3.78 | Therapy-related acute leukemia in two patients with multiple sclerosis treated with Mitoxantrone. ( Colovic, N; Dencic Fekete, M; Djordjevic, V; Drulovic, J; Kraguljac Kurtovic, N; Suvajdzic, N; Tomin, D; Vidovic, A, 2012) |
| " The experience with mitoxantrone (MIX) especially in the first trimenon is very limited, until now only one case of a pregnant woman with MS who was exposed to MIX in early pregnancy and delivered a growth restricted but healthy child was published." | 3.77 | A newborn with Pierre Robin sequence after preconceptional mitoxantrone exposure of a female with multiple sclerosis. ( Chan, A; Epplen, J; Gold, R; Hellwig, K; Schimrigk, S, 2011) |
| "The objective in this paper is to compare the cumulative incidence and incidence density of therapy-related acute myeloid leukaemia in two cohorts of patients with multiple sclerosis treated with mitoxantrone, and with previously reported data in the literature." | 3.75 | Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required. ( Abellán, I; Belenguer, A; Boscá, I; Casanova, B; Coret, F; Fernández, P; Magraner, MJ; Mallada, J; Montalbán, X; Pascual, AM; Sanz, MA; Sempere, AP; Téllez, N, 2009) |
| "Mitoxantrone is an approved drug for patients with worsening relapsing-remitting, secondary progressive and progressive relapsing multiple sclerosis (MS)." | 3.73 | Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone. ( Goffette, S; Morandini, E; Sindic, CJ; van Pesch, V; Vanoverschelde, JL, 2005) |
| "Mitoxantrone (MX) has demonstrated efficacy in multiple sclerosis (MS), but its immunologic mechanisms of action are poorly understood." | 2.72 | Immunological studies of mitoxantrone in primary progressive MS. ( Cotleur, AC; Fox, RJ; Lee, JC; Pelfrey, CM; Zamor, N, 2006) |
| "Mitoxantrone is an antineoplastic drug, recently approved for treatment of multiple sclerosis." | 2.72 | Mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis. ( Etemadifar, M; Hamzehloo, A, 2006) |
| "Mitoxantrone is an antineoplastic agent also used for the treatment of multiple sclerosis (MS)." | 2.72 | In vivo effects of mitoxantrone on the production of pro- and anti-inflammatory cytokines by peripheral blood mononuclear cells of secondary progressive multiple sclerosis patients. ( Angelucci, F; Batocchi, AP; Caggiula, M; Frisullo, G; Mirabella, M; Nociti, V; Patanella, K; Sancricca, C; Tonali, PA, 2006) |
| "Mitoxantrone is a recently approved drug for patients with secondary progressive multiple sclerosis (SPMS)." | 2.71 | Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. ( Abbey, EE; Avasarala, JR; Clifford, DB; Cross, AH; Siegel, BA; Singer, BA, 2003) |
| "Mitoxantrone (mitox) has been shown to be effective for secondary progressive (SP) and relapsing-remitting multiple sclerosis (MS)." | 2.71 | [The effect of combined mitoxantrone and methylprednisolone therapy in primary and secondary progressive multiple sclerosis. An applied study in 65 patients]. ( Brandt, T; Gross, A; Hohlfeld, R; Jahn, K; Strupp, M; Zingler, VC, 2005) |
| "It is hoped that therapeutics in primary progressive multiple sclerosis will continue to expand and effective therapeutic agents will be developed." | 2.71 | Interferon beta-1a in primary progressive multiple sclerosis. ( Leary, SM; Thompson, AJ, 2003) |
| "Mitoxantrone (MX) has been approved by the Food and Drug Administration (FDA) for the treatment of patients with worsening relapsing-remitting (RR) or secondary progressive (SP) multiple sclerosis (MS)." | 2.42 | Mitoxantrone in progressive multiple sclerosis: when and how to treat? ( Gonsette, RE, 2003) |
| "Mitoxantrone (Novantrone) was the first drug approved in western Europe and North America for treatment of secondary progressive multiple sclerosis (SPMS) and progressive relapsing MS (PRMS)." | 2.42 | Mitoxantrone as a potential therapy for primary progressive multiple sclerosis. ( Fox, RJ; Goodkin, DE; Kita, M; Pelletier, D; Stone, J; Stüve, O; Zamvil, SS, 2004) |
| "Mitoxantrone (MITOX) has been used to treat patients with aggressive multiple sclerosis (MS) for decades." | 1.48 | Clinical follow-up of 411 patients with relapsing and progressive multiple sclerosis 10 years after discontinuing mitoxantrone treatment: a real-life cohort study. ( Chartier, N; Dahan, C; Debouverie, M; Epstein, J; Guillemin, F; Mathey, G; Michaud, M; Pittion-Vouyovitch, S; Soudant, M, 2018) |
| "41 mitoxantrone-treated PPMS-patients, 155 mitoxantrone-treated RP/SPMS-patients and 43 PPMS-controls were retrospectively assessed for clinical therapy-response and in correlation with four single-nucleotide-polymorphisms in ABCB1- and ABCG2-genes." | 1.42 | Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: a multi-center, retrospective analysis. ( Chan, A; Comabella, M; Fleischer, V; Gold, R; Grey Née Cotte, S; Kruse, N; Montalban, X; Salmen Née Stroet, A; Starck, M; von Ahsen, N; Winkelmann, A; Zettl, UK; Zipp, F, 2015) |
| " Continuing research is needed to establish its efficacy and safety profile in a multinational collaboration with careful follow-up of adverse events." | 1.40 | Safety and efficacy of mitoxantrone in pediatric patients with aggressive multiple sclerosis. ( Abtahi, SH; Afzali, P; Etemadifar, M; Fereidan-Esfahani, M; Murray, RT; Nourian, SM; Ramagopalan, SV, 2014) |
| "Mitoxantrone treatment in MS is associated with long-term major potential harms - leukaemia (LK) and cardiotoxicity (CT)." | 1.39 | Long-term treatment risks in multiple sclerosis: risk knowledge and risk perception in a large cohort of mitoxantrone-treated patients. ( Elias, WG; Heesen, C; Hofmann, A; Kasper, J; Köpke, S; Pauly, I; Repenthin, J; Rosenkranz, T; Stellmann, JP; Ufer, F; Weber, T, 2013) |
| "Mitoxantrone (MX) is a potent immunosuppressant that is licensed as escalation therapy for the treatment of active multiple sclerosis (MS)." | 1.37 | Stability of cognitive functions under mitoxantrone therapy in patients with progressive multiple sclerosis: a pilot analysis. ( Gold, R; Klotz, P; Lee, DH; Linker, RA; Schröder, A, 2011) |
| "Treatment options for secondary progressive multiple sclerosis (SPMS) are limited." | 1.36 | Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis. ( Akehurst, R; Confavreux, C; Farge-Bancel, D; Kozak, T; Madan, J; Mancardi, GL; Muraro, PA; Rafia, R; Saccardi, R; Sharrack, B; Snowden, J; Tappenden, P, 2010) |
| "Mitoxantrone is an useful and clinically effective drug in MS and its major limitation is the potencial cardiotoxicity due to cumulative dose (140 mg)." | 1.33 | Mitoxantrone in secondarily progressive multiple sclerosis: a series of 18 patients. ( Arruda, WO; de Oliveira, Mde S; Montú, MB; Ramina, R, 2005) |
| "Fifty secondary progressive multiple sclerosis (SPMS) patients who had lost one or more EDSS points in the prior two years were selected to receive either cyclophosphamide (25 patients, 13 females, 12 males, F/M = 1." | 1.33 | Mitoxantrone versus cyclophosphamide in secondary-progressive multiple sclerosis: a comparative study. ( Battistin, L; Calabrese, M; Gallo, P; Perini, P; Ranzato, F; Tiberio, M, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 37 (60.66) | 29.6817 |
| 2010's | 21 (34.43) | 24.3611 |
| 2020's | 3 (4.92) | 2.80 |
| Authors | Studies |
|---|---|
| Lefort, M | 1 |
| Le Corre, G | 1 |
| Le Page, E | 2 |
| Rizzato, C | 1 |
| Le Port, D | 1 |
| Michel, L | 1 |
| Kerbrat, A | 1 |
| Leray, E | 2 |
| Edan, G | 4 |
| Foo, EC | 1 |
| Russell, M | 1 |
| Lily, O | 1 |
| Ford, HL | 1 |
| Lis, M | 1 |
| Niedziela, N | 1 |
| Nowak-Kiczmer, M | 1 |
| Kubicka-Bączyk, K | 1 |
| Adamczyk-Sowa, M | 1 |
| Doshi, A | 1 |
| Chataway, J | 1 |
| Marrie, RA | 1 |
| Montalban, X | 4 |
| Chartier, N | 1 |
| Epstein, J | 1 |
| Soudant, M | 1 |
| Dahan, C | 1 |
| Michaud, M | 1 |
| Pittion-Vouyovitch, S | 3 |
| Guillemin, F | 1 |
| Debouverie, M | 3 |
| Mathey, G | 1 |
| Axelsson, M | 3 |
| Malmeström, C | 3 |
| Gunnarsson, M | 1 |
| Zetterberg, H | 3 |
| Sundström, P | 1 |
| Lycke, J | 3 |
| Svenningsson, A | 1 |
| Martinelli Boneschi, F | 1 |
| Vacchi, L | 2 |
| Rovaris, M | 1 |
| Capra, R | 1 |
| Comi, G | 1 |
| Filippini, G | 1 |
| Del Giovane, C | 1 |
| D'Amico, R | 1 |
| Di Pietrantonj, C | 1 |
| Beecher, D | 1 |
| Salanti, G | 1 |
| Rivera, VM | 1 |
| Jeffery, DR | 2 |
| Weinstock-Guttman, B | 1 |
| Bock, D | 1 |
| Dangond, F | 1 |
| Etemadifar, M | 2 |
| Afzali, P | 1 |
| Abtahi, SH | 1 |
| Ramagopalan, SV | 1 |
| Nourian, SM | 1 |
| Murray, RT | 1 |
| Fereidan-Esfahani, M | 1 |
| Grey Née Cotte, S | 1 |
| Salmen Née Stroet, A | 1 |
| von Ahsen, N | 1 |
| Starck, M | 2 |
| Winkelmann, A | 1 |
| Zettl, UK | 1 |
| Comabella, M | 1 |
| Zipp, F | 2 |
| Fleischer, V | 1 |
| Kruse, N | 1 |
| Gold, R | 5 |
| Chan, A | 3 |
| Mancardi, GL | 2 |
| Sormani, MP | 1 |
| Gualandi, F | 1 |
| Saiz, A | 1 |
| Carreras, E | 1 |
| Merelli, E | 1 |
| Donelli, A | 1 |
| Lugaresi, A | 1 |
| Di Bartolomeo, P | 1 |
| Rottoli, MR | 1 |
| Rambaldi, A | 1 |
| Amato, MP | 2 |
| Massacesi, L | 1 |
| Di Gioia, M | 1 |
| Vuolo, L | 1 |
| Currò, D | 1 |
| Roccatagliata, L | 1 |
| Filippi, M | 1 |
| Aguglia, U | 1 |
| Iacopino, P | 1 |
| Farge, D | 1 |
| Saccardi, R | 2 |
| Öhrfelt, A | 1 |
| Novakova, L | 1 |
| Heslegrave, A | 1 |
| Blennow, K | 2 |
| Kinner, M | 1 |
| Hoepner, R | 1 |
| Klotz, P | 2 |
| Prehn, C | 1 |
| Faissner, S | 1 |
| Salmen, A | 1 |
| Linker, RA | 2 |
| Pascual, AM | 1 |
| Téllez, N | 1 |
| Boscá, I | 1 |
| Mallada, J | 1 |
| Belenguer, A | 1 |
| Abellán, I | 1 |
| Sempere, AP | 1 |
| Fernández, P | 1 |
| Magraner, MJ | 1 |
| Coret, F | 1 |
| Sanz, MA | 1 |
| Casanova, B | 1 |
| Tappenden, P | 1 |
| Confavreux, C | 1 |
| Sharrack, B | 1 |
| Muraro, PA | 1 |
| Kozak, T | 1 |
| Farge-Bancel, D | 1 |
| Madan, J | 1 |
| Rafia, R | 1 |
| Akehurst, R | 1 |
| Snowden, J | 1 |
| Schröder, A | 1 |
| Lee, DH | 1 |
| Hellwig, K | 1 |
| Schimrigk, S | 1 |
| Epplen, J | 1 |
| Colovic, N | 1 |
| Suvajdzic, N | 1 |
| Kraguljac Kurtovic, N | 1 |
| Djordjevic, V | 1 |
| Dencic Fekete, M | 1 |
| Drulovic, J | 1 |
| Vidovic, A | 1 |
| Tomin, D | 1 |
| Havla, J | 1 |
| Kümpfel, T | 1 |
| Hohlfeld, R | 2 |
| Chanvillard, C | 1 |
| Millward, JM | 1 |
| Lozano, M | 1 |
| Hamann, I | 1 |
| Paul, F | 1 |
| Dörr, J | 1 |
| Infante-Duarte, C | 1 |
| Hofmann, A | 1 |
| Stellmann, JP | 1 |
| Kasper, J | 1 |
| Ufer, F | 1 |
| Elias, WG | 1 |
| Pauly, I | 1 |
| Repenthin, J | 1 |
| Rosenkranz, T | 1 |
| Weber, T | 1 |
| Köpke, S | 1 |
| Heesen, C | 1 |
| Augutis, K | 1 |
| Portelius, E | 1 |
| Brinkmalm, G | 1 |
| Andreasson, U | 1 |
| Gustavsson, MK | 1 |
| Mattsson, N | 1 |
| Gonsette, RE | 2 |
| Leary, SM | 1 |
| Thompson, AJ | 1 |
| Avasarala, JR | 1 |
| Cross, AH | 1 |
| Clifford, DB | 1 |
| Singer, BA | 1 |
| Siegel, BA | 1 |
| Abbey, EE | 1 |
| Chaudhuri, A | 1 |
| Behan, PO | 1 |
| Touchette, DR | 1 |
| Durgin, TL | 1 |
| Wanke, LA | 1 |
| Goodkin, DE | 2 |
| Kieseier, BC | 1 |
| Hartung, HP | 2 |
| Ozawa, K | 1 |
| Stüve, O | 1 |
| Kita, M | 1 |
| Pelletier, D | 1 |
| Fox, RJ | 2 |
| Stone, J | 1 |
| Zamvil, SS | 1 |
| Vandenberghe, N | 1 |
| Morrissey, SP | 2 |
| Anxionnat, R | 1 |
| Vespignani, H | 2 |
| Voltz, R | 1 |
| Zingler, V | 1 |
| Strupp, M | 2 |
| Kolb, HJ | 1 |
| Herndon, R | 1 |
| Csépány, T | 1 |
| Bereczki, D | 1 |
| Zingler, VC | 1 |
| Jahn, K | 1 |
| Gross, A | 1 |
| Brandt, T | 1 |
| Goffette, S | 1 |
| van Pesch, V | 1 |
| Vanoverschelde, JL | 1 |
| Morandini, E | 1 |
| Sindic, CJ | 1 |
| Benesova, Y | 1 |
| Stourac, P | 1 |
| Beranek, M | 1 |
| Kadanka, Z | 1 |
| Montú, MB | 1 |
| Arruda, WO | 1 |
| de Oliveira, Mde S | 1 |
| Ramina, R | 1 |
| Krapf, H | 1 |
| Zenker, O | 1 |
| Zwingers, T | 1 |
| Gonsette, R | 1 |
| Perini, P | 1 |
| Calabrese, M | 1 |
| Tiberio, M | 1 |
| Ranzato, F | 1 |
| Battistin, L | 1 |
| Gallo, P | 1 |
| Goris, A | 1 |
| Maranian, M | 1 |
| Walton, A | 1 |
| Yeo, TW | 1 |
| Ban, M | 1 |
| Gray, J | 1 |
| Dubois, B | 1 |
| Compston, A | 1 |
| Sawcer, S | 1 |
| Pelfrey, CM | 1 |
| Cotleur, AC | 1 |
| Zamor, N | 1 |
| Lee, JC | 1 |
| Hamzehloo, A | 1 |
| Nadeau, SE | 1 |
| Lebrun, C | 1 |
| Alchaar, H | 1 |
| Candito, M | 1 |
| Bourg, V | 1 |
| Chatel, M | 1 |
| Angelucci, F | 1 |
| Batocchi, AP | 1 |
| Caggiula, M | 1 |
| Frisullo, G | 1 |
| Patanella, K | 1 |
| Sancricca, C | 1 |
| Nociti, V | 1 |
| Tonali, PA | 1 |
| Mirabella, M | 1 |
| Rieckmann, P | 3 |
| Taillandier, L | 1 |
| Louis, S | 1 |
| Wasay, M | 1 |
| Ali, S | 1 |
| Khatri, IA | 1 |
| Hassan, A | 1 |
| Asif, M | 1 |
| Zakiullah, N | 1 |
| Ahmed, A | 1 |
| Malik, A | 1 |
| Khealani, B | 1 |
| Haq, A | 1 |
| Fredrikson, S | 1 |
| Zipoli, V | 1 |
| Portaccio, E | 1 |
| Hakiki, B | 1 |
| Siracusa, G | 1 |
| Sorbi, S | 1 |
| Cursiefen, S | 1 |
| Flachenecker, P | 1 |
| Toyka, KV | 1 |
| Kilpatrick, TJ | 1 |
| Butzkueven, H | 1 |
| Jain, KK | 1 |
| Rio, J | 1 |
| Lublin, FD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Use of Cellular Stromal Vascular Fraction (cSVF) for Select Multiple Sclerosis, Autoimmune, Inflammatory, and Neurologic Conditions: Clinical Interventional Study of Adverse Events and Clinical Outcomes Using Autologous Stem-Stromal Cells.[NCT02939859] | Phase 1 | 0 participants (Actual) | Interventional | 2018-12-15 | Withdrawn (stopped due to Withdrawn [COVID restrictions prevent patient enrollment or treatment. Clinical Trial facility is being closed due to viral limitations and loss of staff to perform]) | ||
| Evaluation of the Safety and Efficacy of Reduced-intensity Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (AHSCT) in Multiple Sclerosis[NCT03113162] | Phase 1 | 15 participants (Anticipated) | Interventional | 2015-05-29 | Recruiting | ||
| A Randomised, Double Blinded Cross-over Study Comparing the Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis[NCT01149525] | Phase 3 | 59 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
17 reviews available for mitoxantrone and Chronic Progressive Multiple Sclerosis
| Article | Year |
|---|---|
Multiple sclerosis, a treatable disease .
Topics: Adjuvants, Immunologic; Alemtuzumab; Crotonates; Demyelinating Diseases; Dimethyl Fumarate; Fingolim | 2017 |
Mitoxantrone for multiple sclerosis.
Topics: Disease Progression; Humans; Immunosuppressive Agents; Mitoxantrone; Multiple Sclerosis; Multiple Sc | 2013 |
Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
Topics: Antibodies, Monoclonal, Humanized; Glatiramer Acetate; Humans; Immunologic Factors; Immunosuppressiv | 2013 |
[2012: Update on diagnosis and treatment of multiple sclerosis].
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Brain; Combined Modality Therapy; Diagnosis | 2012 |
Mitoxantrone in progressive multiple sclerosis: when and how to treat?
Topics: Disability Evaluation; Drug Evaluation; Humans; Mitoxantrone; Multiple Sclerosis, Chronic Progressiv | 2003 |
Current disease-modifying therapies in multiple sclerosis.
Topics: Adjuvants, Immunologic; Analgesics; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azath | 2003 |
[Immunologic therapy for secondary and primary progressive multiple sclerosis].
Topics: Adjuvants, Immunologic; Humans; Immunosuppressive Agents; Immunotherapy; Interferon beta-1a; Interfe | 2003 |
[Aggressive multiple sclerosis. Definition and specific therapeutic indication].
Topics: Adjuvants, Immunologic; Adult; Analgesics; Anti-Inflammatory Agents; Clinical Trials as Topic; Diagn | 2004 |
A comparison of the benefits of mitoxantrone and other recent therapeutic approaches in multiple sclerosis.
Topics: Adjuvants, Immunologic; Antioxidants; Clinical Trials as Topic; Cost-Benefit Analysis; Drug Administ | 2004 |
Mitoxantrone as a potential therapy for primary progressive multiple sclerosis.
Topics: Humans; Immunosuppressive Agents; Mitoxantrone; Multiple Sclerosis, Chronic Progressive | 2004 |
Mitoxantrone therapy in multiple sclerosis and acute leukaemia: a case report out of 644 treated patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chromosome Inversion; C | 2004 |
Review of mitoxantrone in the treatment of multiple sclerosis.
Topics: Animals; Clinical Trials as Topic; Encephalomyelitis, Autoimmune, Experimental; Humans; Immunosuppre | 2004 |
[Immunomodulatory therapy in multiple sclerosis].
Topics: Adjuvants, Immunologic; Cognition; Drug Administration Schedule; Glatiramer Acetate; Humans; Immunos | 2004 |
Immunosuppressive therapy is valuable in aggressive multiple sclerosis.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Cyclophosphamide; gamma-Globulins; Hematopoietic St | 2000 |
Evaluation of mitoxantrone for the treatment of multiple sclerosis.
Topics: Animals; Female; Humans; Mitoxantrone; Multiple Sclerosis, Chronic Progressive; Pregnancy | 2000 |
Primary progressive multiple sclerosis.
Topics: Glatiramer Acetate; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Interferons; Mit | 2001 |
Therapeutic approaches to secondary progressive multiple sclerosis.
Topics: Anti-Inflammatory Agents; Azathioprine; Bone Marrow Transplantation; Cladribine; Clinical Trials as | 2002 |
15 trials available for mitoxantrone and Chronic Progressive Multiple Sclerosis
| Article | Year |
|---|---|
Calcium-phosphate homeostasis in secondary progressive multiple sclerosis patients during mitoxantrone therapy.
Topics: Adult; Calcium; Female; Homeostasis; Humans; Immunosuppressive Agents; Male; Middle Aged; Mitoxantro | 2021 |
Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study.
Topics: Adult; Aged; Female; Heart Failure; Humans; Leukemia; Male; Middle Aged; Mitoxantrone; Multiple Scle | 2013 |
Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial.
Topics: Adult; Antineoplastic Agents; Female; Gadolinium; Hematopoietic Stem Cell Transplantation; Humans; I | 2015 |
Mitoxantrone induces natural killer cell maturation in patients with secondary progressive multiple sclerosis.
Topics: Adult; Aged; Antineoplastic Agents; B-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Count; Cell Diff | 2012 |
Interferon beta-1a in primary progressive multiple sclerosis.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Antineoplastic Agents; Disability Evaluation; Disease Pro | 2003 |
Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis.
Topics: Adult; Antineoplastic Agents; Female; Humans; Injections, Intravenous; Male; Middle Aged; Mitoxantro | 2003 |
[The effect of combined mitoxantrone and methylprednisolone therapy in primary and secondary progressive multiple sclerosis. An applied study in 65 patients].
Topics: Adult; Aged; Analgesics; Disease Progression; Drug Combinations; Female; Humans; Male; Methylprednis | 2005 |
Mitoxantrone therapy in rapidly worsening multiple sclerosis.
Topics: Disease Progression; Female; Humans; Male; Middle Aged; Mitoxantrone; Multiple Sclerosis, Chronic Pr | 2005 |
Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial.
Topics: Adult; Antineoplastic Agents; Central Nervous System; Disease Progression; Dose-Response Relationshi | 2005 |
CD24 Ala/Val polymorphism and multiple sclerosis.
Topics: Alanine; CD24 Antigen; Chemotaxis, Leukocyte; Double-Blind Method; Female; Humans; Longitudinal Stud | 2006 |
Immunological studies of mitoxantrone in primary progressive MS.
Topics: Adult; CD4-CD8 Ratio; Double-Blind Method; Female; Humans; Leukocyte Common Antigens; Longitudinal S | 2006 |
Mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis.
Topics: Adult; Antineoplastic Agents; Dose-Response Relationship, Drug; Echocardiography; Electrocardiograph | 2006 |
Levocarnitine administration in multiple sclerosis patients with immunosuppressive therapy-induced fatigue.
Topics: Acetylcarnitine; Adolescent; Adult; Cyclophosphamide; Fatigue; Female; Humans; Immunosuppressive Age | 2006 |
In vivo effects of mitoxantrone on the production of pro- and anti-inflammatory cytokines by peripheral blood mononuclear cells of secondary progressive multiple sclerosis patients.
Topics: Adult; Antineoplastic Agents; Cells, Cultured; Cytokines; Enzyme-Linked Immunosorbent Assay; Female; | 2006 |
Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety.
Topics: Adult; Alkylating Agents; Antineoplastic Agents; Blood Cell Count; Cyclophosphamide; Disease Progres | 2008 |
29 other studies available for mitoxantrone and Chronic Progressive Multiple Sclerosis
| Article | Year |
|---|---|
Ten-year follow-up after mitoxantrone induction for early highly active relapsing-remitting multiple sclerosis: An observational study of 100 consecutive patients.
Topics: Follow-Up Studies; Humans; Mitoxantrone; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive | 2022 |
Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone.
Topics: Humans; Mitoxantrone; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosi | 2020 |
Disease-modifying therapy in multiple sclerosis: Two guidelines (almost) passing in the night.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Female; Humans; Immunog | 2018 |
Clinical follow-up of 411 patients with relapsing and progressive multiple sclerosis 10 years after discontinuing mitoxantrone treatment: a real-life cohort study.
Topics: Adult; Cohort Studies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Mitoxantrone; Multiple | 2018 |
Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Axons; Biomarkers; Chemokine CXCL13; Enzyme-Lin | 2014 |
Safety and efficacy of mitoxantrone in pediatric patients with aggressive multiple sclerosis.
Topics: Adolescent; Child; Female; Humans; Immunosuppressive Agents; Male; Mitoxantrone; Multiple Sclerosis, | 2014 |
Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: a multi-center, retrospective analysis.
Topics: Adult; Analgesics; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, | 2015 |
Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone.
Topics: Adult; Biomarkers; Female; Follow-Up Studies; Humans; Immunologic Factors; Male; Membrane Glycoprote | 2016 |
Immunotherapy Improves Cognitive Function in Secondary Progressive Multiple Sclerosis.
Topics: Adolescent; Adult; Cognition Disorders; Disability Evaluation; Female; Humans; Immunosuppressive Age | 2016 |
Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Child; Cohort Studies; Fem | 2009 |
Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis.
Topics: Adolescent; Adult; Cost-Benefit Analysis; Female; Hematopoietic Stem Cell Transplantation; Humans; M | 2010 |
Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study.
Topics: Adult; Amenorrhea; Female; France; Heart Failure; Humans; Immunologic Factors; Leukemia; Male; Middl | 2011 |
Stability of cognitive functions under mitoxantrone therapy in patients with progressive multiple sclerosis: a pilot analysis.
Topics: Adult; Cognition; Depression; Executive Function; Female; Follow-Up Studies; Humans; Immunosuppressi | 2011 |
A newborn with Pierre Robin sequence after preconceptional mitoxantrone exposure of a female with multiple sclerosis.
Topics: Abnormalities, Drug-Induced; Adult; Antiemetics; Antineoplastic Agents; Female; Humans; Infant, Newb | 2011 |
Therapy-related acute leukemia in two patients with multiple sclerosis treated with Mitoxantrone.
Topics: Acute Disease; Adult; Female; Humans; Leukemia; Male; Middle Aged; Mitoxantrone; Multiple Sclerosis, | 2012 |
Long-term treatment risks in multiple sclerosis: risk knowledge and risk perception in a large cohort of mitoxantrone-treated patients.
Topics: Cohort Studies; Female; Health Knowledge, Attitudes, Practice; Humans; Male; Middle Aged; Mitoxantro | 2013 |
Cerebrospinal fluid biomarkers of β-amyloid metabolism in multiple sclerosis.
Topics: Adult; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Antibodies, Monoclonal, Humanized; Bio | 2013 |
Mitoxantrone trial in multiple sclerosis.
Topics: Bias; Disability Evaluation; Double-Blind Method; Female; Humans; Immunosuppressive Agents; Male; Mi | 2003 |
A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-1b in the treatment of patients with secondary progressive or progressive relapsing multiple sclerosis.
Topics: Adjuvants, Immunologic; Cost-Benefit Analysis; Disability Evaluation; Health Care Costs; Humans; Ins | 2003 |
Predictive parameters of mitoxantrone effectiveness in the treatment of multiple sclerosis.
Topics: Adult; Disability Evaluation; Disease Progression; Female; Humans; Magnetic Resonance Imaging; Male; | 2004 |
Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone.
Topics: Adult; Cohort Studies; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Mitoxant | 2005 |
Mitoxantrone in secondarily progressive multiple sclerosis: a series of 18 patients.
Topics: Adult; Anti-Inflammatory Agents; Dose-Response Relationship, Drug; Echocardiography; Female; Humans; | 2005 |
Mitoxantrone versus cyclophosphamide in secondary-progressive multiple sclerosis: a comparative study.
Topics: Adult; Cyclophosphamide; Drug Administration Schedule; Drug Costs; Female; Humans; Immunosuppressive | 2006 |
Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial.
Topics: Adult; Brain; Contrast Media; Disease Progression; Gadolinium; Humans; Mitoxantrone; Multiple Sclero | 2006 |
[Escalating immunomodulatory therapy of multiple sclerosis. Update (September 2006)].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Dose-Response Relationship, Drug; Drug Ad | 2006 |
Clinical follow-up of 304 patients with multiple sclerosis three years after mitoxantrone treatment.
Topics: Antineoplastic Agents; Disability Evaluation; Female; Follow-Up Studies; Glatiramer Acetate; Humans; | 2007 |
Multiple sclerosis in Pakistan.
Topics: Adolescent; Adult; Antineoplastic Agents; Female; Humans; Immunologic Factors; Immunosuppressive Age | 2007 |
[Recent advances in the pathogenesis and immunotherapy of multiple sclerosis].
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Cerebr | 2007 |
Escalating immunotherapy with mitoxantrone in patients with very active relapsing-remitting or progressive multiple sclerosis.
Topics: Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Immunosuppres | 2000 |